• Yutaka Endo, Kazunari Sasaki, Zorays Moazzam, Selamawit Woldesenbet, Jason Yang, Henrique Araujo Lima, Laura Alaimo, Muhammad Musaab Munir, Chanza F Shaikh, Austin Schenk, Minoru Kitago, and Timothy M Pawlik.
• Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH.
• Ann. Surg. 2023 Aug 1; 278 (2): 230238230-238.

ObjectiveWe sought to evaluate the impact of liver transplantation (LT) programs on the prognosis of hepatocellular carcinoma (HCC) patients who underwent liver resection (LR) and noncurative intent treatment.BackgroundLT programs have an array of resources and services that would positively affect the prognosis of patients with HCC.MethodsPatients who underwent LT, LR, radiotherapy (RT), or chemotherapy (CTx) for HCC between 2004 and 2018 were included in the National Cancer Database. Institutions with LT programs were defined as those that performed 1 or more LT for at least 5 years. Centers were stratified by hospital volume. The impact of LT programs was assessed after propensity score matching to achieve covariate balance.ResultsA total of 71,735 patients were identified, of which 7997 received LT (11.1%), 12,683 LR (17.7%), 15,675 RT (21.9%), and 35,380 CTx (49.3%). Among a total of 1267 distinct institutions, 94 (7.4%) were categorized as LT programs. Designation as an LT program was also associated with a high volume of LR and noncurative intent treatment (both P <0.001). After propensity score matching, LT programs were associated with better survival among LR and noncurative intent treatment patients. Although hospital volume was also associated with improved prognosis, LT programs were associated with additional survival benefits in noncurative intent treatment. On the other hand, no such benefit was noted in patients who underwent LR.ConclusionsThe presence of an LT program was associated with a higher volume of LR and noncurative intent treatment. Furthermore, designation as an LT program had a "halo effect" on the prognosis of patients undergoing RT/CTx that went beyond the procedure-volume effect.Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

24 keywords...

hide…